cyc 202 has been researched along with irinotecan in 3 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | cyc 202 (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Abal, M; Bras-Goncalves, R; De Cremoux, P; Fsihi, H; Judde, JG; Louvard, D; Magdelenat, H; Poupon, MF; Robine, S | 1 |
| Ardelt, MA; Brandl, L; De Toni, EN; Ehrlich, SM; Gerbes, AL; Kirchner, T; Lehr, T; Liebl, J; Mayr, D; Vollmar, AM; Zahler, S | 1 |
3 other study(ies) available for cyc 202 and irinotecan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.
Topics: Camptothecin; CDC2 Protein Kinase; Cell Cycle; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Activation; Enzyme Inhibitors; HT29 Cells; Humans; Irinotecan; Mutation; Purines; Roscovitine; Tumor Suppressor Protein p53 | 2004 |
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, SCID; Purines; RNA, Neoplasm; Roscovitine; Treatment Outcome | 2015 |